CYP19A1 and breast carcinoma: In a cohort of stages I-II and operable stage III breast cancer patients, it has been estimated that hormone receptor-(HR-) positive premenopausal patients carrying the long allele of the CYP19 TTTA polymorphism have a significantly longer disease-free survival (DFS) and overall survival (OS) than those without the long allele [10].